secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evelo Biosciences, Inc. (—)
CIK:        0001694665
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001193125-23-022876
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Evelo Biosciences cuts 45% workforce; Phase 2 atopic dermatitis trial fails primary endpoint
--------------------------------------------------------------------------------

- Workforce reduction of 48 employees (45% of headcount); estimated $2.7M charges, cash runway extended into Q3 2023.
- Phase 2 trial of EDP1815 in atopic dermatitis failed primary endpoint (EASI-50) in three cohorts due to high placebo rates; fourth cohort data expected Q2 2023.
- Positive regulatory feedback from FDA, EMA, MHRA for Phase 3 plans of EDP1815 in psoriasis; clear path to global registration.
- Dosing started for Phase 1 of EDP2939 (EV product) in psoriasis; Phase 2a dosing planned Q1 2023; data H2 2023.
- CFO Marella Thorell appointed principal accounting officer after CAO departure; CEO search halted, Simba Gill remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/0001193125-23-022876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1694665/000119312523022876/d344481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-022876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer